Nano vaccine and preparation method thereof
A nano-vaccine, a type of technology, applied in nanotechnology, nanotechnology, nanomedicine, etc., can solve the problem of not being able to accept immune adjuvant and tumor-specific antigen peptide at the same time, and reducing adjuvant/tumor-specific antigen peptide combination therapy efficacy, increase immune-related toxic and side effects, etc., to achieve the effect of improving residence time, improving endocytosis, and improving immune response
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0049] A preparation method of nano vaccine, comprising the steps of:
[0050] 1. Synthesis of polypeptide-maleimide-docosahexaenoic acid / peptide-mal-DHA
[0051] 1.1 Prepare the antigen peptide for later use, the N-terminal of the antigen is connected to the -Cys-(a)-(b) sequence, (a) is a hydrophilic group, and (b) is a cathepsin cleavage site group;
[0052] 1.2N-(2-Aminoethyl)maleimide and docosahexaenoic acid undergo a condensation reaction to obtain an intermediate product I;
[0053] 2,2'-Dithiodiethanol and docosahexaenoic acid are dissolved in dichloromethane, the condensing agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, the base is Under the condition of N,N-diisopropylethylamine, the reaction was carried out at 43°C for 24 hours, the solvent was spin-dried, and the intermediate product I (DHA-mal) was obtained after separation and extraction through a silica gel column;
[0054] 1.3 The final product peptide-mal-DHA is obtained by Michael addition reactio...
Embodiment 2
[0067] The preparation method of embodiment 2 nano vaccine
[0068] (A) A linker sequence CSSVVR is added to the front of the sequence of model antigen ovalbumin (ovalbumin, OVA, amino acid sequence is SIINFEKL) 257-264, synthesized by Zhejiang Ontolaisi Biotechnology Co., Ltd.;
[0069] N-(2-aminoethyl)maleimide and linolenic acid are subjected to a condensation reaction to obtain an intermediate product I, and then the intermediate product I and the antigen are subjected to a Michael addition reaction to obtain OVA covalently coupled linolenic acid: wherein The cysteine on C is used to connect the highly hydrophobic DHA, so that the modified peptide is in the form of one end hydrophobic and one end hydrophilic, which is conducive to the formation of self-assembled nanoparticles; the VVR sequence is the cleavage site of cathepsin S , when the nano-vaccine particles were endocytized by DC cells, the model antigen OVA was released under the action of cathepsin S in the lysoso...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


